Mucopolysaccharidosis VI
18
2
3
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
2 terminated out of 18 trials
83.3%
-3.2% vs benchmark
17%
3 trials in Phase 3/4
50%
5 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (18)
Registry of Patients Diagnosed With Lysosomal Storage Diseases
MPS (RaDiCo Cohort) (RaDiCo-MPS)
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Baby Detect : Genomic Newborn Screening
Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
Human Placental-Derived Stem Cell Transplantation
A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
Clinical Trial of Growth Hormone in MPS I, II, and VI
Stem Cell Transplantation for Hurler
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Study of rhASB in Patients With Mucopolysaccharidosis VI
Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation